-

01:03:23 PM

ABEO Stock News

ABEO - Abeona Therapeutics Inc

09/26/23 7:30 AM

Nasdaq : ABEO

low float

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy,

RHEA-AI

positive

09/12/23 7:30 AM

Nasdaq : ABEO

managementlow float

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition to

RHEA-AI

neutral

09/07/23 7:30 AM

Nasdaq : ABEO

conferenceslow float

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2023: A company presentation at the H.C. Wainwright Annual Global Investment Conference on

RHEA-AI

neutral

08/30/23 7:30 AM

Nasdaq : ABEO

low float

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company’s intention to proceed with the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EB-101, its investigational autologous,

RHEA-AI

neutral

08/08/23 7:30 AM

Nasdaq : ABEO

earningslow float

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering in July allow initiation of pre-commercial launch activities for EB-101 Cash on hand plus proceeds from registered direct offering projected to fund operations

RHEA-AI

neutral

07/28/23 7:30 AM

Nasdaq : ABEO

low float

Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The

RHEA-AI

neutral

07/19/23 8:30 AM

Nasdaq : ABEO

low float

Abeona Therapeutics Joins Rare Disease Company Coalition

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has joined the Rare Disease Company Coalition (RDCC), an alliance of life science companies committed to discovering, developing, and delivering therapies for patients impacted by rare

RHEA-AI

neutral

07/07/23 8:30 AM

Nasdaq : ABEO

offeringlow float

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses. “Our existing

RHEA-AI

neutral

07/03/23 8:45 AM

Nasdaq : ABEO

offeringlow float

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million at-the-market from select existing investors, primarily to fund initiation of the Company’s launch preparations in anticipation of the EB-101 Biologics License

RHEA-AI

neutral

06/09/23 7:30 AM

Nasdaq : ABEO

low float

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received feedback from the U.S. Food and Drug Administration (FDA) on June 8, 2023, in which the Company gained the Agency’s alignment on the data required to establish retroviral vector

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

ABEO Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttps://abeonatherapeutics.com/
Security nameAbeona Therapeutics Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUS

About Abeona Therapeutics Inc

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t